

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

DATE MAILED: 04/20/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/845,162	05/01/2001	Dennis W. Wahr	08386.0003	2628
22852	7590 04/20/2004		EXAMINER	
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER			THOMPSON, KATHRYN L	
LLP 1300 I STRE	EET, NW		ART UNIT	PAPER NUMBER
WASHINGT	TON, DC 20005		3763	17

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>್ತ್</b>				4		
		Application No.	Applicant(s)	<del> /</del>		
		09/845,162	WAHR ET AL.			
	Offic Action Summary	Examiner	Art Unit			
		Kathryn L Thompson	3763			
Period fo	Th MAILING DATE of this communior Reply	cation appears on the cover sheet w	ith the correspondenc address			
THE - Exte after - If the - If NC - Failt Any	ORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNI nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comm a period for reply specified above is less than thirty (30) period for reply is specified above, the maximum state to reply within the set or extended period for reply reply received by the Office later than three months a led patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no event, however, may a unication. )) days, a reply within the statutory minimum of thi tutory period will apply and will expire SIX (6) MOI will. by statute. cause the application to become A	reply be timely filed  ty (30) days will be considered timely.  NTHS from the mailing date of this communical  BANDONED (35 U.S.C. § 133).	tion.		
Status						
1)  🛛	Responsive to communication(s) file	d on <i>01 May 2001</i> .				
2a)[		2b)⊠ This action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 1-148 and 179-222 is/are p 4a) Of the above claim(s) 1-148 and Claim(s) is/are allowed. Claim(s) 200-222 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restrict	<u>179-199</u> is/are withdrawn from cons	sideration.			
Applicat	tion Papers		•			
,	The specification is objected to by the		ated to by the Everniner			
10) 🔼	The drawing(s) filed on <u>01 May 2001</u> Applicant may not request that any object					
	Replacement drawing sheet(s) including	·		1(d).		
11)	The oath or declaration is objected to	·				
Priority	under 35 U.S.C. § 119					
a)	<ul><li>2. Certified copies of the priority</li><li>3. Copies of the certified copies</li></ul>	documents have been received. documents have been received in a of the priority documents have been nal Bureau (PCT Rule 17.2(a)).	Application No n received in this National Stage			
2) Noti	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (P rmation Disclosure Statement(s) (PTO-1449 or	TO-948) Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application (PTO-152)			
	er No(s)/Mail Date <u>4, 5, 7-10, 14-16</u> .	6) Other:				

Art Unit: 3763

### **DETAILED ACTION**

#### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-74, 148, 179-222, drawn to a method for treating a blood vessel, classified in class 604, subclass 500.
- II. Claims 75-147, drawn to an evacuation sheath assembly, classified in class 604, subclass 93.01.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either: (1) the process as claimed can be practiced by another materially different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case the apparatus as claimed can be used to practice another and materially different process such as delivering medicament via the stent to the wound site of the blood vessel.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: 1) Figure 1A; 2) Figure 1C; 3) Figure 2A; 4) Figure 3A;

Art Unit: 3763

5) Figure 4A; 6) Figures 6A-6I; 7) Figures 7A-7I; 8) Figures 8A-8I; 9) Figures 9A-9H; 10) Figure 10A.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.



Art Unit: 3763

During a telephone conversation with Ms. Burke a provisional election was made without traverse to prosecute the invention of Group I, Species 6, Figures 6A-6I, claims 200-222. Affirmation of this election must be made by applicant in replying to this Office action. Claims 1-148 and 179-199 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 200-204, 207-216, and 219-222 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pierpont (US 5,484,412) in view of Parodi (US 6,206,868). Pierpont teaches all of the claimed limitations except subsequent to dilating the lesion, using active suction to induce retrograde flow within the blood vessel. Parodi discloses subsequent to dilating the lesion, using active suction to induce retrograde flow within the blood vessel (Column 1, Lines 14-20). It would have been obvious to one with



Art Unit: 3763

ordinary skill in the art to use the teachings of Parodi to modify the invention of Pierpont and include the step of suctioning in order to induce retrograde flow in the vessel of interest.

Claims 205, 206, 217, and 218 are rejected under 35 U.S.C. 103(a) as being unpatentable over Pierpont in view of Parodi, further in view of Barbut (US 6,146,370). Pierpont and Parodi disclose all of the claimed limitations except advancing a stent into the blood vessel. Barbut discloses advancing a stent into the blood vessel (Figure 8A, Column 7, Lines 1-5). It would have been obvious to one with ordinary skill in the art to use the teachings of Barbut and modify the invention of Pierpont and Parodi in order to compress the lesion in the blood vessel and enlarge the lumenal diameter, thereby generating embolic debris.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kathryn L Thompson whose telephone number is 703-305-3286. The examiner can normally be reached on 8:30 AM - 6:00 PM: 1st Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 703-308-3552. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.



Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KLT

BRIAN L. CASLER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700